| Literature DB >> 31106488 |
Yongjian Tian1, Tingting Zeng1, Liming Tan1, Yang Wu1, Jianlin Yu1, Jiayi Huang1, Zihuang Pei1.
Abstract
BACKGROUND: Antineutrophil cytoplasmic autoantibodies against neutrophil granule bactericidal/permeability-increasing protein (BPI-ANCA) has been found in many inflammatory diseases, such as COPD, which can reduce the killing effect of BPI on Gram-negative bacteria. This study was aimed to assess the clinical significance of BPI-ANCA detecting in COPD patients with Pseudomonas aeruginosa (P aeruginosa) colonization.Entities:
Keywords: zzm321990Pseudomonas aeruginosazzm321990; antineutrophil cytoplasm autoantibodies; bactericidal/permeability-increasing protein; chronic obstructive pulmonary disease; cytokines
Mesh:
Substances:
Year: 2019 PMID: 31106488 PMCID: PMC6642326 DOI: 10.1002/jcla.22908
Source DB: PubMed Journal: J Clin Lab Anal ISSN: 0887-8013 Impact factor: 2.352
Figure 1Flowchart of participants' inclusion and exclusion criteria
General information of subjects and IgG‐BPI‐ANCA detection rate
| Parameters |
|
| HC group |
|
|---|---|---|---|---|
| Age (y) | 60.03 ± 11.17 | 61.04 ± 13.23 | 58.63 ± 12.05 | 0.245 |
| Sex (n, %) | ||||
| Male | 152 (70.37%) | 182 (74.59%) | 62 (62.00%) | 0.066 |
| Female | 64 (29.63%) | 62 (25.41%) | 38 (38.00%) | |
| BMI (kg/m2) | 25.20 ± 3.22 | 24.65 ± 2.82 | 24.56 ± 3.41 | 0.101 |
| Smoking status (n, %) | ||||
| Never smoked | 58 (26.85%) | 74 (30.33%) | 21 (21.00%) | 0.054 |
| Past smoking | 119 (55.09%) | 115 (47.13%) | 48 (48.00%) | |
| Current smoking | 39 (18.06%) | 57 (23.37%) | 31 (31.00%) | |
| Smoking history (pack year) | 43.06 ± 13.10 | 41.90 ± 12.68 | 40.14 ± 13.44 | 0.174 |
| Illness duration (y) | 12.32 ± 5.23 | 10.77 ± 4.95 | ‐ | 0.001 |
| Hospital admission within 6 mo | ||||
| Yes | 116 (53.70%) | 107 (43.85%) | ‐ | 0.035 |
| No | 100 (46.30%) | 137 (56.15%) | ‐ | |
| Family oxygen therapy | ||||
| Yes | 18 (8.33%) | 20 (8.20%) | ‐ | 0.958 |
| No | 198 (91.67%) | 224 (91.80%) | ‐ | |
| Taken glucocorticoid | ||||
| Yes | 128 (59.26%) | 142 (58.20%) | ‐ | 0.817 |
| No | 88 (40.74%) | 102 (41.80%) | ‐ | |
| BPI‐ANCA (n, %) | ||||
| (+) | 104 (48.15%) | 6 (2.46%) | 0 (0%) | 0.000 |
| (−) | 112 (51.85%) | 238 (97.54%) | 0 (0%) | |
Abbreviations: BMI, body mass index; BPI‐ANCA, antineutrophil cytoplasmic autoantibodies against neutrophil granule bactericidal/permeability‐increasing protein; HC, healthy control.
Tested by one‐way ANOVA test
Tested by chi‐square test
Comparison of general data between patients with BPI‐ANCA(+) and BPI‐ANCA(‐) of patients with COPD combined with Pseudomonas aeruginosa colonization
| Parameters |
BPI‐ANCA(+) |
BPI‐ANCA(−) |
|
|---|---|---|---|
| Age (y) | 61.08 ± 10.12 | 59.05 ± 12.02 | 0.992 |
| Sex | |||
| Male | 75 (72.12%) | 77 (68.75%) | 0.588 |
| Female | 29 (27.88%) | 35 (31.25%) | |
| BMI (kg/m2) | 25.49 ± 2.94 | 24.92 ± 3.26 | 0.288 |
| Smoking status (n, %) | |||
| Never smoked | 19 (24.04%) | 33 (29.47%) | 0.079 |
| Past smoking | 68 (59.62%) | 50 (50.89%) | |
| Current smoking | 17 (16.34%) | 30 (19.64%) | |
| Smoking history (pack year) | 44.71 ± 14.64 | 41.27 ± 11.02 | 0.052 |
| FEV1%pred | 50.31 ± 7.94 | 52.91 ± 7.14 | 0.012 |
| FEV1/FVC (%) | 48.35 ± 8.95 | 50.61 ± 6.27 | 0.037 |
Abbreviations: BMI, body mass index; BPI‐ANCA, antineutrophil cytoplasmic autoantibodies against neutrophil granule bactericidal/permeability‐increasing protein; CRP, C‐reactive protein; FEV1%pred: predicted% forced expiratory volume in 1 min; FEV1/FVC: forced expiratory volume in one second/forced vital capacity ratio; NEU, neutrophil.
Tested by independent data t test.
Tested by chi‐square test.
Serum inflammatory markers were compared between the two groups
| Parameters |
BPI‐ANCA(+) |
BPI‐ANCA(−) |
|
|---|---|---|---|
| TNF‐α (pg/mL) | 45.69 ± 19.93 | 33.31 ± 14.58 | 0.000 |
| IL‐6 (pg/mL) | 40.61 ± 12.60 | 29.25 ± 7.86 | 0.000 |
| IL‐1β (pg/mL) | 21.95 ± 7.29 | 14.37 ± 6.15 | 0.000 |
| NEU% | 64.14 ± 9.48 | 61.66 ± 8.33 | 0.042 |
| CRP (mg/L) | 8.41 ± 1.09 | 5.34 ± 1.14 | 0.000 |
Data were expressed as mean ± SD and tested by group t test.
Abbreviations: BPI‐ANCA, antineutrophil cytoplasmic autoantibodies against neutrophil granule bactericidal/permeability‐increasing protein; CRP, C‐reactive protein; IL‐1β, interleukin 1β; IL‐6, interleukin 6; NEU, neutrophil; TNF‐α, tumor necrosis factor‐α.
Correlation of FEV1%pred and FEV1/FVC(%) with inflammatory markers
| Parameters | FEV1%pred | FEV1/FVC(%) | ||
|---|---|---|---|---|
|
|
|
|
| |
| TNF‐α | −0.582 | 0.000 | −0.589 | 0.000 |
| IL‐6 | −0.521 | 0.000 | −0.579 | 0.000 |
| IL‐1β | −0.346 | 0.000 | −0.388 | 0.000 |
| CRP | −0.159 | 0.019 | −0.076 | 0.264 |
| NEU (%) | −0.543 | 0.000 | −0.582 | 0.000 |
Abbreviations: CRP, C‐reactive protein; FEV1%pred, predicted% forced expiratory volume in 1 min; FEV1/FVC, forced expiratory volume in one second/forced vital capacity ratio; IL‐1β, interleukin 1β; IL‐6, interleukin 6; NEU, neutrophil; TNF‐α, tumor necrosis factor‐α.
Serum levels of TNF‐α, IL‐6, and IL‐1β at different levels of COPD airflow limitation
| Mild | Moderate | Severe | Very severe |
| |
|---|---|---|---|---|---|
| BPI‐ANCA group (n,%) | |||||
| (+) | 11 (10.58%) | 22 (21.15%) | 33 (31.73%) | 38 (36.54%) | 0.018 |
| (−) | 21 (18.75%) | 35 (31.26%) | 37 (30.35%) | 22 (19.64%) | |
| TNF‐α (pg/mL) | 10.81 ± 6.05 | 28.5 ± 10.25 | 42.10 ± 9.04 | 65.73 ± 14.45 | <0.000 |
| IL‐6 (pg/mL) | 9.63 ± 4.77 | 18.81 ± 8.76 | 32.75 ± 8.95 | 54.18 ± 11.88 | <0.000 |
| IL‐1β (pg/mL) | 3.97 ± 1.08 | 6.49 ± 2.49 | 13.96 ± 6.93 | 27.28 ± 10.43 | <0.000 |
Abbreviations: BPI‐ANCA, antineutrophil cytoplasmic autoantibodies against neutrophil granule bactericidal/permeability‐increasing protein antibodies; IL‐1β, interleukin 1β; IL‐6, interleukin 6; TNF‐α, tumor necrosis factor‐α.
Tested by chi‐square test.
Tested by one‐way ANOVA test.